Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s two primary product candidates are, revumenib (SNDX-5613), and axatilimab (SNDX-6352). Co. is developing SNDX-5613, a small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia, and acute myeloid leukemia, or AML, and NPM1 mutant AML. Co. is also developing SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1, in chronic graft-versus-host disease, as well as idiopathic pulmonary fibrosis. We show 34 historical shares outstanding datapoints in our coverage of SNDX's shares outstanding history.
Understanding the changing numbers of SNDX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SNDX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SNDX by allowing them to research SNDX shares outstanding history
as well as any other stock in our coverage universe. |
Free SNDX Email Alerts:
Video: Shares Outstanding Importance
